‘Progenitor exhausted’ (also referred to as ‘stem-like’) PD1+ Slamf6+ CD8 T cells are considered the main responder population in anti-PD1 blockade therapy, in both mouse models and cancer patients45,55–58. The gene discussed is CD8A; the disease is cancer.